The Ophthalmic Devices market market in Austria is anticipated to achieve a revenue of US$231.50m by 2024. It is estimated that the revenue will experience a compound annual growth rate (CAGR 2024 ...

Growth Drivers: Factors fueling market expansion include the growing geriatric demographic, governmental attention to eye care policies, escalating diabetes rates globally, enhanced access to ...

The Ophthalmic Devices market market in Egypt is anticipated to achieve a revenue of US$90.62m by the year 2024. It is expected that the revenue will exhibit a compound annual growth rate (CAGR ...

EssilorLuxottica has acquired French startup Pulse Audition as it looks to embed AI-based speech enhancement into its glasses. One of EssilorLuxottica’s product lines is smart lenses fitted with ...

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging ...

06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its ...

Latanoprost SR is under clinical development by Peregrine Ophthalmic and currently in Phase I for Unspecified Ophthalmological Disorders.

22, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today provided an update on its ongoing restructuring efforts. The Company announced today that Avenue ...

The research team led by Dr. Moon-Hyeong Seo from the Natural Product Drug Development Center at the Korea Institute of ...

Our growth has driven our practices’ technical requirements and increased the complexity of managing disparate clinical operations across multiple systems,” said Kurt Williams, CEO at Eye Care ...

Beacon Therapeutics has raised $170m in a Series B funding round to accelerate the development of its lead asset AGTC-501, for X-linked retinitis pigmentosa (XLRP). The financing round was led by ...